Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 56

1.

Selective Raf inhibition in cancer therapy.

Khazak V, Astsaturov I, Serebriiskii IG, Golemis EA.

Expert Opin Ther Targets. 2007 Dec;11(12):1587-609. Review. Erratum in: Expert Opin Ther Targets. 2009 Sep;13(9):1135.

2.

Targeting Raf-kinase: molecular rationales and translational issues.

Caraglia M, Tassone P, Marra M, Budillon A, Venuta S, Tagliaferri P.

Ann Oncol. 2006 Jun;17 Suppl 7:vii124-7. Review.

PMID:
16760274
3.

Raf kinase inhibitors in oncology.

Strumberg D, Seeber S.

Onkologie. 2005 Feb;28(2):101-7. Review.

PMID:
15665559
4.

Novel small molecule Raf kinase inhibitors for targeted cancer therapeutics.

Kim DH, Sim T.

Arch Pharm Res. 2012 Mar;35(4):605-15. doi: 10.1007/s12272-012-0403-5. Epub 2012 May 3. Review.

PMID:
22553052
5.

Phase I/II RAF kinase inhibitors in cancer therapy.

Turajlic S, Ali Z, Yousaf N, Larkin J.

Expert Opin Investig Drugs. 2013 Jun;22(6):739-49. doi: 10.1517/13543784.2013.797964. Epub 2013 May 6. Review.

PMID:
23642225
6.

Recent advances in the research and development of RAF kinase inhibitors.

Smith RA, Dumas J, Adnane L, Wilhelm SM.

Curr Top Med Chem. 2006;6(11):1071-89. Review.

PMID:
16842147
7.

Raf kinases: oncogenesis and drug discovery.

Schreck R, Rapp UR.

Int J Cancer. 2006 Nov 15;119(10):2261-71. Review.

8.

RAS/RAF/MEK inhibitors in oncology.

Rusconi P, Caiola E, Broggini M.

Curr Med Chem. 2012;19(8):1164-76. Review.

PMID:
22257058
9.

Raf: a strategic target for therapeutic development against cancer.

Beeram M, Patnaik A, Rowinsky EK.

J Clin Oncol. 2005 Sep 20;23(27):6771-90. Review.

PMID:
16170185
10.

Targeting the Raf kinase cascade in cancer therapy--novel molecular targets and therapeutic strategies.

Lee JT Jr, McCubrey JA.

Expert Opin Ther Targets. 2002 Dec;6(6):659-78. Review.

PMID:
12472379
11.

Bench to bedside: mechanistic principles of targeting the RAF kinase in melanoma.

Rajakulendran T, Adam DN.

Int J Dermatol. 2014 Dec;53(12):1428-33. doi: 10.1111/ijd.12724. Epub 2014 Oct 14. Review.

PMID:
25311997
12.

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.

Roberts PJ, Der CJ.

Oncogene. 2007 May 14;26(22):3291-310. Review.

PMID:
17496923
13.

Development of small-molecule inhibitors of Raf.

Wu S, Guo W, Fang B.

Recent Pat Antiinfect Drug Discov. 2006 Jun;1(2):241-6. Review.

PMID:
18221149
14.

Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.

Matsuda Y, Fukumoto M.

Med Mol Morphol. 2011 Dec;44(4):183-9. doi: 10.1007/s00795-011-0558-z. Epub 2011 Dec 17. Review.

PMID:
22179180
15.

Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway.

Wong KK.

Recent Pat Anticancer Drug Discov. 2009 Jan;4(1):28-35. Review.

PMID:
19149686
16.

Raf-interactome in tuning the complexity and diversity of Raf function.

An S, Yang Y, Ward R, Liu Y, Guo XX, Xu TR.

FEBS J. 2015 Jan;282(1):32-53. doi: 10.1111/febs.13113. Epub 2014 Nov 21. Review.

17.

Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.

Gollob JA, Wilhelm S, Carter C, Kelley SL.

Semin Oncol. 2006 Aug;33(4):392-406. Review.

PMID:
16890795
18.

Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy.

Santarpia L, Lippman SM, El-Naggar AK.

Expert Opin Ther Targets. 2012 Jan;16(1):103-19. doi: 10.1517/14728222.2011.645805. Epub 2012 Jan 12. Review.

19.

Is B-Raf a good therapeutic target for melanoma and other malignancies?

Madhunapantula SV, Robertson GP.

Cancer Res. 2008 Jan 1;68(1):5-8. doi: 10.1158/0008-5472.CAN-07-2038. Review.

20.

Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK.

Martinelli E, Morgillo F, Troiani T, Ciardiello F.

Cancer Treat Rev. 2017 Feb;53:61-69. doi: 10.1016/j.ctrv.2016.12.001. Epub 2016 Dec 30. Review.

PMID:
28073102

Supplemental Content

Support Center